secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001493152-24-015037
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman
-----------------------------------------------------------------

- Dr. Simba Gill appointed Executive Chairman effective April 12, 2024.
- Annual cash fee of $300,000 and grant of 295,300 stock options under 2024 Equity Incentive Plan.
- Dr. Gill has over 35 years of biotech leadership including Maxygen, Systemix, Boehringer Mannheim, Celltech.
- Five-year post-termination non-compete and non-solicitation covenants apply.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/0001493152-24-015037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-015037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer